Preclinical News and Research

RSS

Lab-grown cell models reveal urate triggers vital renal water channels

Mayo Clinic researchers have identified a previously unrecognized way the kidneys regulate water balance - an advance that could lead to improved treatments for polycystic kidney disease (PKD) and other disorders. The study, led by Fouad Chebib, M.D., a nephrologist at Mayo Clinic, is published in the Journal of Clinical Investigation.

16 Jun 2026

Engineered silica nanoparticles destroy prostate tumors in preclinical study

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while enhancing anti-tumor immunity, according to a preclinical study led by investigators at Weill Cornell Medicine and the Cornell College of Engineering.

15 Jun 2026

Lab trials prove copper therapy enhances cognitive function and spatial learning

Monash University researchers have found in laboratory experiments that a drug which delivers copper to the brain significantly reduces toxic Alzheimer's proteins and improves long-term spatial memory.

15 Jun 2026

Injectable wireless device offers new approach to control nerve activity

Researchers from NYU Abu Dhabi, in collaboration with Cleveland Clinic Abu Dhabi, have developed a tiny, injectable medical device that introduces a new approach to treating chronic pain and movement disorders by controlling nerve activity without the need for surgery, batteries, or wires, offering a simpler and less invasive way to treat neurological conditions.

12 Jun 2026

Novel metal-free prodrug suppresses cancer spread in preclinical models

A carefully designed metal-free carbon monoxide prodrug may help prevent some of the deadliest forms of cancer from spreading, according to researchers at Weill Cornell Medicine.

12 Jun 2026

PhoreMost announces lead oncology program and appoints Chief Medical Officer to support clinical entry

PhoreMost Limited, a biotech company focused on turning scientific breakthroughs into life-changing cancer drugs, today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers.

From PhoreMost 12 Jun 2026

Amsterdam UMC researchers overturn long-standing biological pacemaker dogma

Researchers from Amsterdam UMC have overturned a key assumption in the biological pacemaker field.

11 Jun 2026

Intravenous statins during heart attack reduce cardiac muscle damage

Reducing the damage sustained by the heart during a myocardial infarction remains one of the major challenges in cardiology, even when the blocked coronary artery is reopened in a timely manner.

11 Jun 2026

Genetic study links liver enzyme to compulsive cocaine addiction

Researchers at the University of California San Diego have completed a massive genetic study that identifies key biological drivers of cocaine addiction, uncovering a potential new target for treatment that resides in the liver rather than the brain.

11 Jun 2026

New treatment platform delivers full-length mRNA for Duchenne muscular dystrophy

A new treatment platform developed by researchers at The University of Texas MD Anderson Cancer Center was able to deliver messenger RNA (mRNA) of the full-length DMD gene into preclinical models of Duchenne muscular dystrophy, successfully restoring the production of an important muscle protein, dystrophin, and dramatically improving muscle strength, endurance and function in vivo.

11 Jun 2026

Scientists target NOX4 protein in skeletal muscle to combat aging

The powerful role of exercise in maintaining skeletal muscle could be the key to improving health and resilience in older age, according to new research from Monash University.

11 Jun 2026

A hidden immune pathway may help explain why Alzheimer’s inflammation persists

Researchers found that KAT7 promotes CMPK2-driven mitochondrial DNA release in microglia, activating inflammatory cGAS-STING and NLRP3 pathways linked to Alzheimer’s disease.

11 Jun 2026

Scientists reveal how cGAS-STING fuels brain inflammation and neurodegeneration

The cGAS-STING pathway is emerging as a key driver of chronic neuroinflammation through its effects on glial activation, neuronal stress, blood-brain barrier integrity, and type I interferon signaling. The review highlights why selective, context-dependent modulation of cGAS-STING could help treat neurodegenerative diseases, while preserving its essential roles in antiviral defense and tumor surveillance.

10 Jun 2026

New geroscience initiative aims to accelerate anti‑aging therapies

Albert Einstein College of Medicine has launched the Batia and Idan Ofer program for Validation of Interventions Targeting Aging and Longevity (BIO-VITAL), a new initiative designed to help biotechnology and pharmaceutical companies advance therapies that target the biology of aging.

9 Jun 2026

Scientists use inactive virus to safe-deliver spasticity-reversing spinal genes

Muscle spasticity is a common and often debilitating consequence of spinal cord injury that can significantly affect mobility and quality of life. Spasticity is a condition in which muscles become abnormally stiff or tight because of disrupted nerve signaling, often causing exaggerated reflexes, involuntary muscle spasms and difficulty with movement.

9 Jun 2026

Blocking immune pathway slows Huntington disease in mouse models

Huntington disease is a rare, inherited brain disorder that progressively destroys nerve cells, leading to worsening movement, cognitive and psychiatric symptoms.

8 Jun 2026

Brain-targeted estrogen reduces breast cancer treatment side effects

Most breast cancers are worsened by estrogens. To combat the recurrence of these cancers, clinicians treat patients with inhibitors for estrogen production, like letrozole. But many patients do not adhere to this treatment due to negative side effects.

8 Jun 2026

Infant receives world's first gene therapy for WOREE syndrome

An eight-month-old infant with a severe genetic epilepsy has become the first patient in the world to receive an experimental gene replacement therapy designed to restore the function of the WWOX gene directly in the brain.

8 Jun 2026

Flu drugs may reduce cognitive decline in people with HIV

A class of flu drugs may reduce cognitive decline and premature aging in people living with chronic viral infection, reports a new study led by Northwestern University that began with blood samples from people with HIV and extended into preclinical drug trials.

5 Jun 2026

New topical gel uses repurposed MS drug to heal burns

Researchers at the Terasaki Institute for Biomedical Innovation and the University of Arizona College of Medicine have developed a topical gel formulation with 4-aminopyridine (4-AP), to treat burn wounds, achieving near-complete closure in 21 days.

4 Jun 2026